ストックスクリーナーアプリを入手
3.07
2.85%
-0.09
前日終値:
$3.16
開ける：
$3.16
24時間の取引高:
154.70K
Relative Volume:
0.34
時価総額：
$69.58M
収益：
$66.58M
当期純損益:
$-19.95M
株価収益率:
-3.3377
EPS:
-0.9198
ネットキャッシュフロー:
$-14.27M
1週間 パフォーマンス:
-6.69%
1か月 パフォーマンス:
-6.40%
6か月 パフォーマンス:
-68.48%
1年 パフォーマンス:
-8.36%
1日の値動き範囲:
$3.02
$3.20
1週間の範囲:
$2.91
$3.787
52週間の値動き範囲:
$2.91
$12.23
Exagen Inc Stock (XGN) Company Profile
Compare XGN vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
3.07 | 69.58M | 66.58M | -19.95M | -14.27M | -0.9198 |
|
TMO
Thermo Fisher Scientific Inc
|
464.37 | 172.51B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.32 | 132.46B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
573.82 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.51 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
286.57 | 28.11B | 3.17B | 642.63M | 516.49M | 10.77 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-11 | 開始されました | B. Riley Securities | Buy |
| 2025-07-30 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-07-23 | 開始されました | Craig Hallum | Buy |
| 2022-08-05 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-04-15 | 開始されました | Canaccord Genuity | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | 開始されました | BTIG Research | Buy |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-10-14 | 開始されました | Cowen | Outperform |
| 2019-10-14 | 開始されました | William Blair | Outperform |
すべてを表示
Exagen Inc (XGN) 最新ニュース
Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat and Cautious 2026 Outl - AD HOC NEWS
Exagen stock price target lowered to $10 by Canaccord on margin outlook - Investing.com UK
KeyBanc cuts Exagen stock price target on pricing headwinds - Investing.com Nigeria
Exagen (XGN): Canaccord Genuity Lowers Price Target to $10.00 | - GuruFocus
Canaccord Genuity Group Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat
Exagen Inc. 2025 Annual Report: Innovative AVISE® Autoimmune Disease Testing, Business Strategy, Pipeline, and Intellectual Property Overview - Minichart
Analyst John Wilkin Lowers Price Target for Exagen (XGN) | XGN S - GuruFocus
KeyBanc cuts Exagen stock price target on pricing headwinds By Investing.com - Investing.com India
Exagen (NASDAQ:XGN) Price Target Cut to $10.00 by Analysts at Craig Hallum - MarketBeat
XGN: Keybanc Lowers Price Target to $10, Maintains Overweight Ra - GuruFocus
KeyCorp Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat
Exagen Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-03-11 - Seeking Alpha
Exagen stock price target lowered to $10 by Canaccord on margin outlook By Investing.com - Investing.com Canada
Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence - MSN
BTIG cuts Exagen stock price target to $9 on lower revenue outlook By Investing.com - Investing.com India
William Blair Maintains Outperform on Exagen Inc. (XGN) March 2026 - Meyka
BTIG cuts Exagen stock price target to $9 on lower revenue outlook - Investing.com India
Exagen (XGN) Rating Maintained by BTIG, Price Target Lowered to $9.00 | XGN Stock News - GuruFocus
Exagen (NASDAQ:XGN) Price Target Lowered to $9.00 at BTIG Research - MarketBeat
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments By GuruFocus - Investing.com Canada
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments - GuruFocus
4 Analysts Have This To Say About Exagen - Benzinga
Exagen stock maintains Outperform rating at William Blair By Investing.com - Investing.com India
Exagen stock maintains Outperform rating at William Blair - Investing.com Australia
Exagen Q4 2025 Earnings Call Transcript - MarketBeat
Exagen Inc. Reports Strong Q4 and Full-Year 2025 Financial Results – Earnings Press Release March 2026 - Minichart
Exagen Q4 Earnings Call Highlights - Yahoo Finance
Exagen (XGN) Achieves Record Q4 Revenue, Driven by Test Volume G - GuruFocus
XGN Forecasts Significant Revenue Growth by 2026 - GuruFocus
Earnings call transcript: Exagen Inc. misses Q4 2025 earnings expectations - Investing.com Nigeria
Exagen 2025 10-K: Revenue $66.6M; net loss $(19.95)M - TradingView
XGN: Record 2025 revenue of $66.6M (+19.7%) with net loss of $20.0M; strong AVISE® CTD growth - TradingView
Exagen Inc. (NASDAQ:XGN) Reports Record 2025 Revenue and Provides 2026 Outlook - ChartMill
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Exagen (NASDAQ:XGN) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
EXAGEN DIAGNOSTICS ($XGN) Releases Q4 2025 Earnings - Quiver Quantitative
Exagen reports record 2025 revenue $66.6M, ASP rises to $441; Q4 revenue $16.6M - TradingView
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results - The Manila Times
Exagen Earnings Report: Q4 Overview - Benzinga
BRIEF-Exagen Inc. Q4 Revenue USD 16.631 Million Vs. IBES Estimate USD 16.6 Million - TradingView
Autoimmune tests for over 137,000 patients power Exagen's 20% revenue rise - Stock Titan
Exagen Inc. (XGN) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
A Peek at Exagen's Future Earnings - Benzinga
XGN: B. Riley Securities Lowers Price Target, Maintains Buy Rati - GuruFocus
Insider Sell: Can Exagen Inc grow without dilutionJuly 2025 PreEarnings & AI Driven Stock Reports - baoquankhu1.vn
Aug Spikes: How strong is Exagen Inc. stock balance sheetTrade Analysis Summary & AI Enhanced Trade Execution Alerts - Naître et grandir
Exagen announces resale of up to 1.15M shares - MSN
Exagen Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Exagen Inc. (NASDAQ:XGN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Exagen Inc. (NASDAQ:XGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
John Aballi Sells 15,698 Shares of Exagen (NASDAQ:XGN) Stock - MarketBeat
Exagen Inc (XGN) 財務データ
収益
当期純利益
現金流量
EPS
0.34%
0.59%
大文字化:
|
ボリューム (24 時間):